



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/578,603
Filing Date	May 4, 2006
First Named Inventor	DUFFIELD, Jonathan
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	8024-012-US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): IDS (1 page); Forms PTO/SB/08A & PTO/SB08B (2 pages in duplicate); 8 Journal Articles (102 pages); and Self Addressed Stamped Postcard.
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Express Abandonment Request		
<input type="checkbox"/> Information Disclosure Statement		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Catalyst Law Group, APC		
Signature			
Printed name	David M. Kohn, J.D.		
Date	October 24, 2006	Reg. No.	53,150

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Christina Duenas	Date	October 24, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT
8024-012-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Examiner: TBA
)
DUFFIELD, Jonathan et al.,) Group Art Unit: TBA
)
Serial No.: 10/578,603) Docket No.: 8024-012-US
)
Filed: May 4, 2006) Date Mailed: October 24, 2006
)
For: "Synthesis of Glycopeptides with)
Superior Pharmacokinetic Properties")

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Information Disclosure Statement
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

This document is an Information Disclosure Statement to the above-cited patent application and filed pursuant to 37 C.F.R. § 1.97(b)(3). Therefore, no fee is believed to be due.

Attached are forms PTO/SB/08A and PTO/SB/08B listing documents believed relevant to the subject application. The submission of this document is not intended, nor should it be construed, to constitute an admission that any patent, patent application, article, or other information referred to herein is "prior art" unless specifically designated as such. In fact, applicants submit that these documents do not affect the patentability of the subject invention. In accordance with 37 C.F.R. § 1.97(g), the filing of this information shall not be construed to represent that a search has been made or that no other material information may exist. Neither should its submission be construed to indicate that a thorough search should not be conducted by the Examiner.

It is respectfully requested that the listing of documents in the attached forms be: (1) fully considered by the Patent and Trademark Office during the prosecution of this application; and (2) represented on any patent which may issue on the application. Applicant respectfully requests that copies of the forms PTO/SB/08A/B, as considered and initialed by the Examiner, be returned with the next communication pursuant to the §609 of the Manual of Patent Examining Procedures (MPEP).

The order of the documents listed in the attached forms is to be accorded no particular import, as the order thereof is completely fortuitous. Additionally, the documents are not necessarily analogous art. A copy of each article document listed in the attached forms is enclosed.

It is believed that this disclosure complies with the requirements as set forth under 37 C.F.R. § 1.56, § 1.97, and § 1.98 and §707.05(b) of the MPEP. If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be telephoned at (858) 450-0099 so that any deficiencies can be remedied.

It is further believed that this Information Disclosure Statement is being submitted before the mailing of an Office Action on the merits. Accordingly, no fee is believed to be due under 37 C.F.R. § 197(b)(3). If an Office Action on the merits has in fact been mailed, authorization is hereby given to charge the required fee of \$180.00 under 37 C.F.R. § 1.97(c)(2) and 1.17(p) to Deposit Account No. 502235.


Respectfully submitted,

Date: October 24, 2006



David M. Kohn, J.D.
Reg. No. 53,150

CATALYST LAW GROUP, APC
9710 Scranton Road, Suite 170
San Diego, California 92121
(858) 450-0099
(858) 450-9834 (Fax)



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/578,603
Filing Date	May 4, 2006
First Named Inventor	DUFFIELD, Jonathan
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	8024-012-US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/578,603
			Filing Date	May 4, 2006
			First Named Inventor	DUFFIELD, Jonathan
			Art Unit	TBD
			Examiner Name	TBD
Sheet 2	of 2	Attorney Docket Number	8024-012-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		BOONS, GEERT-JAN, "Strategies in Oligosaccharides Synthesis", Tetrahedron 1996, pp.1095-1121, V.52, No. 4.	
		EGLETON, R.D. et al, "Improved Blood-Brain Barrier Penetration and Enhanced Analgesia...", JPET 2001, pp. 967-972, V. 299, No. 3.	
		MERRIFIELD, R.B., "Solid Phase Peptide Synthesis", J. Am. Chem. Soc. 1963, 85, 2149-2154.	
		PALIAN, MICHAEL et al., "Glycopeptide-Membrane Interactions...", J. Am. Chem. Soc. 2003, pp. 5823-5831, V.125.	
		POWELL, MICHAEL et al, "Peptide Stability in Drug Development...", Pharm. Res. 1993, pp. 1268-1273, V. 10.	
		SHIN, YOUNGSOOK et al, "Fmoc-Based Synthesis of Peptide...", J. Am. Chem. Soc. 1999, V. 121, pp. 11684-11689.	
		TOSHIMA, KAZUNOBU, "Glycosyl flourides in glycosidations", Carbohydr. Res. 2000, V. 327, pp. 15-26.	
		TOSHIMA, K. and TATSUTA, K., "Recent Progress in O-Glycosylation Methods and ...", Chemical Review, 1993, V. 93, pp.1503-1531.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.